Knocked out by head trauma

Add SNX-111 to a long list of compounds that have failed in head trauma, with Elan Pharmaceuticals and partner Warner-Lambert Co. terminating a Phase III trial of the agent based on an interim analysis of more than 200 patients.

The news last week could well have been the finishing blow for trials of the compound in that indication, where heterogeneity of the patient population has claimed other compounds (see Technology Briefing, Oct. 12). Indeed, the SNX-111 studies already had been suspended twice before, although Elan last week